{
  "id": "56d1f790f22319765a000001",
  "type": "factoid",
  "question": "Which gene harbors the mutation T790M?",
  "ideal_answer": "The T790M mutation refers to the mutation in exon 20 of the EGFR gene",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25667490",
    "http://www.ncbi.nlm.nih.gov/pubmed/25384171",
    "http://www.ncbi.nlm.nih.gov/pubmed/26056478",
    "http://www.ncbi.nlm.nih.gov/pubmed/25682017",
    "http://www.ncbi.nlm.nih.gov/pubmed/25806347",
    "http://www.ncbi.nlm.nih.gov/pubmed/25483995",
    "http://www.ncbi.nlm.nih.gov/pubmed/25323938",
    "http://www.ncbi.nlm.nih.gov/pubmed/25939061",
    "http://www.ncbi.nlm.nih.gov/pubmed/26124670",
    "http://www.ncbi.nlm.nih.gov/pubmed/26058074",
    "http://www.ncbi.nlm.nih.gov/pubmed/26396685",
    "http://www.ncbi.nlm.nih.gov/pubmed/25382705"
  ],
  "snippets": [
    {
      "text": "Nearly one half of all cases of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small-cell lung cancer (NSCLC) are due to the T790M mutation in EGFR exon 20. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682017",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two types of epidermal growth factor receptor (EGFR) mutations in exon 19 and exon 21 (ex19del and L858R) are prevalent in lung cancer patients and sensitive to targeted EGFR inhibition. A resistance mutation in exon 20 (T790M) has been found to accompany drug treatment when patients relapse. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25939061",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "However, resistance to the EGFR TKIs develops mostly secondary to T790M mutation in exon 20. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058074",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In nonsmall cell lung cancer (NSCLC), the threonine(790)-methionine(790) (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26396685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both AKT and MEK inhibition contributed to cell death independent of erlotinib in the T790M-containing H1975 and the EGFR-WT cell lines tested.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25323938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The EGFR T790M mutation is generally considered to be the molecular genetic basis of acquired TKI resistance",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483995",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667490",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In EGFR-mutated NSCLC cell lines with the acquired resistance threonine-to-methionine mutation in codon 790 (T790M) mutation, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25384171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To overcome T790M-mediated acquired resistance of lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), second generation ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25382705",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Approximately 50% of cases of acquired resistance (AR) are due to a secondary T790M mutation in exon 20 of the EGFR gene;",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25806347",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "EGFR, epidermal growth factor receptor"
}